Roche's Transfer Of Assets To Arrowhead May Create Most-Comprehensive RNAi Firm

After an expensive foray into RNAi, Roche is handing off its substantial portfolio to Arrowhead, in exchange for a 10% stake in the company and right-of-first-negotiation to programs and earn-out potential.